Inactive Instrument

Coeptis Therapeutics, Inc. Stock OTC Markets

COEP

US19207C1045

Chart Coeptis Therapeutics, Inc.

Duration

Period

Style

Dynamic Chart

Latest news about Coeptis Therapeutics, Inc.

Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Coeptis Therapeutics Holdings, Inc. Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK	Feb. 26	CI
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-In-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections	Feb. 07	CI
Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Coeptis Therapeutics Holdings, Inc. announced that it has received $2 million in funding	Nov. 02	CI
Coeptis Therapeutics Holdings, Inc. announced that it expects to receive $2 million in funding	23-10-23	CI
Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology	23-10-11	CI
Coeptis Therapeutics Holdings, Inc. announced that it expects to receive $0.5 million in funding	23-09-28	CI
Ladenburg Thalmann Starts Coeptis Therapeutics Holdings at Buy, $3 Price Target	23-09-22	MT
Certain Pre-Funded Warrants of Coeptis Therapeutics Holdings, Inc. are subject to a Lock-Up Agreement Ending on 13-SEP-2023.	23-09-12	CI
Certain Options of Coeptis Therapeutics Holdings, Inc. are subject to a Lock-Up Agreement Ending on 13-SEP-2023.	23-09-12	CI
Certain Warrants of Coeptis Therapeutics Holdings, Inc. are subject to a Lock-Up Agreement Ending on 13-SEP-2023.	23-09-12	CI
Certain Common Stock of Coeptis Therapeutics Holdings, Inc. are subject to a Lock-Up Agreement Ending on 13-SEP-2023.	23-09-12	CI
Coeptis Therapeutics Holdings, Inc. Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer	23-08-30	CI
Coeptis Therapeutics Holdings, Inc. Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics	23-08-17	CI

More news

Analyst Recommendations on Coeptis Therapeutics, Inc.

Ladenburg Thalmann Starts Coeptis Therapeutics Holdings at Buy, $3 Price Target	23-09-22	MT
EF Hutton Assumes COEP at Coeptis Therapeutics at Buy With $10 Price Target	23-05-25	MT
JonesTrading Initiates Coeptis Therapeutics at Buy With $4 Price Target	23-04-19	MT
EF Hutton Initiates Coeptis Therapeutics With Buy Rating, Price Target is $6	22-12-12	MT

More recommendations

Press releases Coeptis Therapeutics, Inc.

Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on receiving the 2024 Chancellor s Distinguished Research Award	Apr. 03	AQ
Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award	Apr. 02	PR
Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK	Feb. 27	AQ
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections	Feb. 07	PR
Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024	Jan. 04	PR

More press releases

Managers and Directors - Coeptis Therapeutics, Inc.

Managers	Title	Age	Since
David Mehalick CEO	Chief Executive Officer	56	22-10-27
Brian Cogley DFI	Director of Finance/CFO	38	23-05-16
Daniel Yerace COO	Chief Operating Officer	41	22-10-27

Members of the board	Title	Age	Since
Philippe Deschamps BRD	Director/Board Member	62	22-10-27
Christopher Cochran BRD	Director/Board Member	55	22-10-27
Christine Sheehy CMP	Compliance Officer	57	22-10-27

More insiders

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, including Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc. and Coeptis Pharmaceuticals, LLC., is a biopharmaceutical company. The Company owns, acquires, and develops cell therapy technologies for cancer and other diseases. Its product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen chimeric antigen receptor (CAR) T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms, which the Company is developing with VyGen-Bio and medical researchers at the Karolinska Institute. Its CAR therapy is a treatment for cancer in which a patient's T cells are genetically engineered to recognize cancer cells to target and destroy them.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+24.60%	672B
NOVO NORDISK A/S	+24.08%	550B
JOHNSON & JOHNSON	-5.63%	351B
MERCK & CO., INC.	+15.37%	317B
ABBVIE INC.	+7.38%	292B
ASTRAZENECA PLC	+3.26%	211B
NOVARTIS AG	+0.78%	203B
PFIZER, INC.	-9.69%	144B
AMGEN INC.	-6.63%	141B

Other Pharmaceuticals

Sales 2024 *	-	Sales 2025 *	-	Capitalization	11.95M
Net income 2024 *	-26M	Net income 2025 *	-35M	EV / Sales 2024 *	-
Net cash position 2024 *	-	Net cash position 2025 *	-	EV / Sales 2025 *	-
P/E ratio 2024 *	-0.43 x	P/E ratio 2025 *	-0.38 x	Employees	6
Yield 2024 *	-	Yield 2025 *	-	Free-Float	67.46%